China adds 3 psychotropic drugs to controlled list, effective Oct 2026

This regulatory move tightens China's control over specific psychotropic substances, signaling a stricter stance on their cross-border trade. The inclusion of customs codes suggests immediate operational impact for importers and exporters, who will need to adjust compliance procedures well ahead of the October 2026 effective date. The exemption for approved domestic preparations indicates a targeted approach, aiming to curb potential misuse while preserving legitimate medical use. The key watch point is whether this foreshadows broader scheduling actions or increased enforcement in related substance categories, which could affect supply chain dynamics for pharmaceutical firms operating in the region.